Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated Jun 05, 2025, titled "Alvotech and Dr. Reddy s enter into Collaboration toCo-Develop Biosimilar Candidate to Keytruda� (pembrolizumab) for global markets.".
Press Release Jun 05 2025
Filed with NSE ·
Watch Dr. Reddy's Laboratories' latest callDr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings Call · Replay · Oct 23Read the transcript of Dr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings Call6ix hasn’t read this filing yet.
Dr. Reddy's Laboratories Ltd. on 6ix
Earlier from Dr. Reddy's Laboratories
- Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
- Dr. Reddy’s Q4 & Full Year FY25 Financial Results
- Press Release Apr 24 2025
- Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
- Press Release Mar 13 2025
Later from Dr. Reddy's Laboratories
- Press Release Jul 15 2025
- Cenra Healthcare and Dr. Reddy's Strengthen Strategic Partnership to Expand Access to Medicines in Taiwan
- Dr. Reddy’s Q1FY26 Financial Results
- Press Release Jul 23 2025
- Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.
Follow Dr. Reddy's Laboratories into a list and get an email when it puts out news.
Follow Dr. Reddy's Laboratories